The size of the Asia Pacific Alzheimer’s disease Therapeutics and Diagnostics Market was worth USD 2663.21 Million in 2021 and estimated to be growing at a CAGR of 5.39%, to reach USD 3462.59 Million by 2026.
The key factors that are boosting the growth of Alzheimer's disease diagnosis and therapeutics market in the Asia Pacific are the increasing percentage of senior citizens and the rise in the prevalence of Alzheimer's in the Asia Pacific region. Technological advancements leading to the expansion of healthcare in developed and developing countries such as China, India, Japan, Malaysia, and others are contributing to the growth of Asia Pacific Alzheimer's disease diagnostics and therapeutics market. Increasing disposable income of the people is another significant factor which is catalyzing the growth of Alzheimer's disease diagnosis and therapeutics market in the Asia Pacific. Increased focus of governments and private organizations for research and development of technologically advanced diagnosing and therapeutic devices is boosting the Asia Pacific Alzheimer's disease diagnosis and therapeutics market.
The emergence of novel and innovative Alzheimer's therapeutics and diagnostics solutions are presumed to create lucrative growth opportunities to key market players in the regional market during the forecast period in Asia pacific. Increasing demand for advanced technologies and therapeutic procedures owing to the increasing prevalence of neurodegenerative disorders and Alzheimer's in the Asia Pacific region is to offer a number of growth opportunities for the stakeholders in the area. Growing economies of the developing countries in the area are leading to shifting in focus of governments to provide better healthcare and develop infrastructure owing to technological advancements is supposed to offer more growth opportunities for the key players functioning in the Alzheimer's disease diagnosis and therapeutics market in the Asia Pacific. Also, less number of market players in the region will offer lucrative opportunities for the newly entered players into the local Alzheimer's disease diagnostics and therapeutics market.
The expensive nature of treatment is the major challenge that is limiting the growth of Alzheimer's disease diagnosis and therapeutics market in the Asia Pacific. Lack of proper reimbursement policies is another significant challenge for Alzheimer's disease diagnosis and therapeutics market in the Asia Pacific.
This research report is segmented & sub-segmented into the following categories:
Developing countries are anticipated to offer lucrative prospects for this market in this region. According to Alzheimer’s disease International in 2015, 58% of people with dementia live in emerging countries, but by 2050 this figure will rise to 68%. The fastest growth in the elderly populace is taking place in China, India, and their south Asian and western Pacific region.
The major companies dominating the APAC Alzheimer’s Disease Therapeutics and Diagnostics market in this region are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H. Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals etc.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapeutics
5.1.1 Introduction
5.1.2 Marketed Drugs
5.1.2.1 NMDA Receptor Antagonists
5.1.2.2 Cholinesterase Inhibitors
5.1.3 Pipeline Drugs
5.1.4 Y-o-Y Growth Analysis, By Therapeutics
5.1.5 Market Attractiveness Analysis, By Therapeutics
5.1.6 Market Share Analysis, By Therapeutics
5.2 Diagnostics
5.2.1 Introduction
5.2.2 Computed tomography scan
5.2.3 Electroencephalography
5.2.4 Lumbar puncture test
5.2.5 Magnetic resonance imaging
5.2.6 Positron emission tomography
5.2.7 Others
5.2.8 Y-o-Y Growth Analysis, By Diagnostics
5.2.9 Market Attractiveness Analysis, By Diagnostics
5.2.10 Market Share Analysis, By Diagnostics
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapeutics
6.1.3.3 By Diagnostics
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapeutics
6.1.4.3 By Diagnostics
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Therapeutics
6.1.5.3 By Diagnostics
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Abbvie Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer Inc.
8.3 AC Immune SA
8.4 Eisai Co Ltd.
8.5 Allergan PLC
8.6 Novartis AG
8.7 Amarantus Bioscience Holdings
8.8 H. Lundbeck A/S
8.9 Anavex LifeSciencescs
8.10 Avid Radiopharmaceuticals
8.11 Forest Laboratories Inc.
8.12 Axon Neuroscience
8.13 Daiichi Sankyo Co
8.14 TauRx Therapeutics Ltd
8.15 Eli Lilly
8.16 F. Hoffmann La Roche AG
8.17 Johnson & Johnson
8.18 GE Healthcare
8.19 Janssen Pharmaceuticals
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
